Under a mutual agreement with the board of directors, longtime Novo Nordisk CEO Lars Fruergaard Jørgensen—who recently shepherded the company through its GLP-1 growth boom—is heading for the exit.

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

Airbus is appointing its top executive in South Asia to be its next head of technology, industry sources said on Friday. Remi ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Procurement Magazine takes a look back at the biggest news from across the industry over the last seven days, including SAP, ...

The British magic circle law firm Freshfields revealed it was serious about a US expansion when it poached star M&A lawyer ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...